Lausanne – SOPHiA GENETICS received the “Salus Partner Excellence in HealthTech Award” at the Convergence in Oncology Summit (Biopôle – Lausanne).
This prize recognizes the company’s progress in the democratization of Data-Driven Medicine.
SOPHiA GENETICS is a health tech company that has developed SOPHiA AI, the most advanced and used technology for Data-Driven Medicine. SOPHiA helps clinicians better diagnose, treat and monitor patients thanks to accurate and standardized clinical genomics analysis. SOPHiA supports the diagnosis of 1 patient every 5 minutes – +250’000 to date.
Upon receiving the award Dr. Jurgi Camblong CEO and co-founder of SOPHiA GENETICS commented: “In the context of Convergence in Oncology, our mission is to allow and encourage knowledge sharing, key to deliver disruptive solutions in the fight against cancer. We are very happy and honored to receive the 2018 Salus Excellence in HealthTech Award. It is again the recognition of our teamwork dedicated to help as many patients as possible worldwide.”
“SOPHiA GENETICS joins a prestigious group of companies recognized by the Salus Partners Excellence in Health Tech Award. They are a great example of the flourishing innovation in Health Tech in Switzerland,” said Dr. Brian Hashemi, Co-Organizer of the Convergence in Oncology Summit and Managing Partner of the investment firm Salus Partners.
Previous winners of the award have been experiencing great momentum: Endosense – a Geneva-based company in cardiac ablation, acquired by St. Jude for CHF300mm. Sapiens – innovation in Deep Brain Stimulation, acquired by Medtronic for USD200mm. Molecular Partners – a Zurich-based Biotech introducing DARPins as a new class of biologicals in ophthalmology and cancer, now on the Swiss Stock Exchange with a market cap of CHF470mm. – PR